drugset / Trial / NCT01200342
Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research is to learn if the combination of Genasense (oblimersen), carboplatin, and paclitaxel (GCP) can help to control metastatic uveal melanoma. The safety of this combination will also be studied.
Timeline
- Start
- 2010-12
- Primary completion
- 2013-09
- Completion
- 2013-09
Outcome
Outcome not reported
Stopped: “Pharmaceutical company no longer manufacturing investigational product.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 6 unknown | Intravenous |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |
| Subject | oblimersen sodium | Antisense oligonucleotide | 900 mg | Intravenous |